<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00056056</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-21011</org_study_id>
    <secondary_id>2004-003701-24</secondary_id>
    <nct_id>NCT00056056</nct_id>
  </id_info>
  <brief_title>Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides</brief_title>
  <official_title>A Randomized, Open-Label Phase III Trial to Evaluate the Efficacy and Safety of Bexarotene (Targretin) Capsules Combined With PUVA, Compared to PUVA Treatment Alone in Patients With Mycosis Fungoides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Ultraviolet light therapy uses light and drugs that make cancer cells more&#xD;
      sensitive to light to kill tumor cells. It is not yet known whether ultraviolet light therapy&#xD;
      is more effective with or without bexarotene in treating mycosis fungoides.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of ultraviolet light therapy&#xD;
      using methoxsalen with or without bexarotene in treating patients who have mycosis fungoides.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine if ultraviolet A light therapy with methoxsalen (PUVA) with or without&#xD;
           bexarotene yields a significantly higher overall response rate in patients with mycosis&#xD;
           fungoides.&#xD;
&#xD;
        -  Compare the overall response rate (CCR and partial response) in patients treated with&#xD;
           these regimens.&#xD;
&#xD;
        -  Compare the duration of CCR and time to relapse of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the number of PUVA sessions necessary to achieve a CCR in these patients.&#xD;
&#xD;
        -  Determine the percentage of dropouts by patients treated with these regimens.&#xD;
&#xD;
        -  Determine the safety of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified&#xD;
      according to participating center, age (60 and under vs over 60), and stage of disease (IB vs&#xD;
      IIA). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive PUVA comprising oral methoxsalen given 2 hours before whole body&#xD;
           ultraviolet A therapy. PUVA is given 3 times per week.&#xD;
&#xD;
        -  Arm II: Patients receive oral bexarotene once daily and PUVA as in arm I. In both arms,&#xD;
           treatment repeats for up to 16 weeks in the absence of complete clinical response,&#xD;
           disease progression, or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 8 weeks until the first documented progression or relapse.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 145 patients will be accrued for this study within 25 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor accrual&#xD;
  </why_stopped>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (complete clinical response [CCR) and partial response [PR])</measure>
    <time_frame>35 months after first patient in</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative dose of UVA required to achieve CCR</measure>
    <time_frame>35 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of PUVA sessions necessary to achieve a CCR</measure>
    <time_frame>35 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CCR as measured by Logrank every 4 weeks during treatment and then every 8 weeks until progression</measure>
    <time_frame>35 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>35 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by CTC v2.0 every 4 weeks during treatment, then every 8 weeks</measure>
    <time_frame>35 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of dropouts as measured by the percentage of cases not completing treatment due to toxicity at the completion of treatment</measure>
    <time_frame>35 months after first patient in</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Bexarotene and PUVA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PUVA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bexarotene</intervention_name>
    <description>The recommended initial dosage of Bexarotene (75 mg Bexarotene capsules to be administered according to body surface area) for patients entered in this trial is 300 mg/m2 /once a day, taken orally, till CCR, PD, unacceptable toxicity, 16 weeks of treatment, whichever comes first</description>
    <arm_group_label>Bexarotene and PUVA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methoxypsoralen</intervention_name>
    <description>The dose of methoxypsoralen, as conventional capsules or liquid-filled capsules, is based on the patient's weight. The standard dose of 0.6 mg/kg will be given to all patients three times weekly - Increasing dose of PUVA according to a set protocol after a Minimal Phototoxic Dose (MPD) testing.</description>
    <arm_group_label>Bexarotene and PUVA</arm_group_label>
    <arm_group_label>PUVA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>UV light therapy</intervention_name>
    <description>Initial UVA light exposure times should be based on the minimal phototoxic dose (MPD) for the specific light source being used. MPD can be determined by irradiating several skin areas 2 cm in diameter with varying light exposure times and determining the exposure time that produces erythema at 72 hours. The initial dose of UVA administered will be 70% of the MPD. The dose of UVA for the subsequent UVA sessions will be increased according to a standard protocol consisting of 20% increments with each successive treatment session depending on the presence of erythema.</description>
    <arm_group_label>Bexarotene and PUVA</arm_group_label>
    <arm_group_label>PUVA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed mycosis fungoides&#xD;
&#xD;
               -  Stage IB or IIA&#xD;
&#xD;
               -  Confirmed by current or prior diagnostic lesion biopsy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 2,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2 times ULN&#xD;
&#xD;
          -  Calcium no greater than 11.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association grade III or IV cardiac insufficiency&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 3 months&#xD;
             after study participation* NOTE: *Women using hormonal contraception must also use a&#xD;
             non-hormonal treatment&#xD;
&#xD;
          -  Fasting triglycerides normal (prior antilipemic agents allowed to reach normalization)&#xD;
&#xD;
          -  Willing and able to avoid prolonged exposure to the sun&#xD;
&#xD;
               -  Willing to limit sun exposure on day of PUVA therapy&#xD;
&#xD;
          -  No prior intolerance of or unresponsiveness to PUVA therapy&#xD;
&#xD;
          -  No other prior or concurrent malignant tumor except adequately treated carcinoma in&#xD;
             situ of the cervix or basal cell or squamous cell skin cancer&#xD;
&#xD;
          -  No prior pancreatitis&#xD;
&#xD;
          -  No other concurrent serious illness or infection that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  No concurrent excessive alcohol consumption&#xD;
&#xD;
          -  No photosensitivity due to intrinsic (e.g., lupus) or extrinsic (e.g., photosensitive&#xD;
             drugs) factors&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance&#xD;
&#xD;
          -  No known contraindications to study drug&#xD;
&#xD;
          -  No known hypersensitivity to retinoids or hypervitaminosis A&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No uncontrolled thyroid disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 3 months since prior interferon therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior systemic combination chemotherapy&#xD;
&#xD;
          -  No prior participation in another study of bexarotene&#xD;
&#xD;
          -  At least 3 months since prior topical chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 1 month since prior topical corticosteroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 6 months since prior total skin electron beam therapy&#xD;
&#xD;
          -  At least 1 month since prior superficial radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 30 days since prior participation in another investigational drug study&#xD;
&#xD;
          -  At least 3 months since prior photopheresis&#xD;
&#xD;
          -  At least 1 month since prior UVB/PUVA phototherapy&#xD;
&#xD;
          -  At least 1 month since prior retinoid class drugs&#xD;
&#xD;
          -  At least 1 month since prior beta-carotene compounds&#xD;
&#xD;
          -  At least 1 month since other prior topical medications (e.g., tar baths)&#xD;
&#xD;
          -  No prior participation in this study&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational drug therapy&#xD;
&#xD;
          -  No concurrent drugs associated with pancreatic toxicity or known to increase&#xD;
             triglyceride concentrations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean J. Whittaker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Thomas' Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karl-Franzens-University Graz</name>
      <address>
        <city>Graz</city>
        <zip>A-8010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus - Universitatskliniken</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ghent University</name>
      <address>
        <city>Gent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>D-32423</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Insular de Gran Canaria</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest German Cancer Center at Eberhard-Karls-University</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik II - Universitaetsklinikum Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>D-</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>County Hospital</name>
      <address>
        <city>Kaposvar</city>
        <zip>H-7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center - Beilinson Campus</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Dermopatico Dell' Immacolata</name>
      <address>
        <city>Rome</city>
        <zip>00167</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Torino</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Cruz i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Senora de la Candelaria</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <zip>38003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas' Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh at Little France</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>March 6, 2003</study_first_submitted>
  <study_first_submitted_qc>March 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2003</study_first_posted>
  <last_update_submitted>July 6, 2018</last_update_submitted>
  <last_update_submitted_qc>July 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bexarotene</mesh_term>
    <mesh_term>Methoxsalen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

